Back to top

Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)

Guggenheim analyst reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $35.00. The company’s shares closed yeste...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcutis Biotherapeutics, Inc. (ARQT)